Gene expression profiling of the synergy of 5-aza-2(′)-deoxycytidine and paclitaxel against renal cell carcinoma

BACKGROUND: Renal cell carcinoma (RCC) is one of the most common kidney cancers and is highly resistant to chemotherapy. We previously demonstrated that 5-aza-2(′)-deoxycytidine (DAC) could significantly increase the susceptibility of renal cell carcinoma (RCC) cells to paclitaxel (PTX) treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Tiandong, Shang, Donghao, Xu, Xiuhong, Tian, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481426/
https://www.ncbi.nlm.nih.gov/pubmed/22950635
http://dx.doi.org/10.1186/1477-7819-10-183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481426/
https://www.ncbi.nlm.nih.gov/pubmed/22950635
http://dx.doi.org/10.1186/1477-7819-10-183

Ejemplares similares